JG26

Item no.	HY-120852-100mg
Manufacturer	MedChem Express
CASRN	1464910-32-4
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	98.14
Citations	[1]Doretta Cuffaro, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12(11):1787-1793.\|[2]Gentili V, et al. JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro. Pharmacol Rep. 2025 Feb;77(1):260-273. \|[3]Zocchi MR, et al. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology. 2015 Dec 29;5(5):e1123367.\|[4]Cuffaro D, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12(11):1787-1793.\|[5]Li K, et al. Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer. J Exp Clin Cancer Res. 2024 Feb 27;43(1):59. \|[6]Kawai T, et al. Pharmacological Inhibition of ADAM17 by a Human-Cross Reactive Antibody and Selective Inhibitor JG26 Prevents Vascular Fibrosis Induced by Angiotensin II in vivo and in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36(suppl_1): A557-A557.
Smiles	O=C([C@@H](CCCNC(N)=O)NS(=O)(C1=CC=C(C=C1)OCC2=CC(Br)=CC(Br)=C2)=O)NO
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Angiotensin-converting Enzyme (ACE); EGFR; ERK; MMP; SARS-CoV
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	594.27
Product Description	JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases[1][2][3][4][5][6].
Manufacturer - Research Area	Cancer; Infection; Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	ADAM10; ADAM17; ADAM8; MMP-12; MMP-14; MMP-8; MMP-9
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-120852-100mg-safety-datasheet.pdf